SLC5A2 and hydrops fetalis: SGLT2 inhibitors, a novel oral hypoglycemic agent, have shown in recent clinical studies to significantly reduce the incidence of composite cardiovascular death or worsening HF events in HF patients with mildly reduced or preserved ejection fraction over a median follow-up of 2.0–2.5 years [35, 36].